Back to Search
JOSEPH BUSE, PHARMD
PHARMD
Oncology Pharmacist
NPI: 1669222857Individual
Specialties, Licenses & Credentials
Pharmacist
Pharmacist
Code: 183500000X
2017034038(MO)
Oncology PharmacistPrimary
Pharmacist — Oncology
Code: 1835X0200X
2017034038(MO)
Research & Publications (20)
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.
PMID 18941734·Diabetologia·2009
8-other
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.
PMID 18945920·Diabetes Care·2009
6-review
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).
PMID 19289857·Diabetes Care·2009
2-rct
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP).
PMID 19626663·Diabetes Metab Res Rev·2009
4-observational
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
PMID 19336625·Diabetes Care·2009
4-observational
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association.
PMID 19147051·J Am Coll Cardiol·2009
6-review
Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes.
PMID 19276235·J Clin Endocrinol Metab·2009
4-observational
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
PMID 19515413·Lancet·2009
4-observational
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
PMID 19095622·Circulation·2009
6-review
Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.
PMID 19092168·Diabetes Care·2009
6-review
Clinical experience with continuous glucose monitoring in adults.
PMID 19469683·Diabetes Technol Ther·2009
8-other
Endothelial dysfunction: associations with exposure to ambient fine particles in diabetic individuals.
PMID 19079718·Environ Health Perspect·2008
7-preclinical
A dead heat: target normal glucose levels in the intensive care unit--but with caution.
PMID 18392805·Diabetologia·2008
8-other
Effects of intensive glucose lowering in type 2 diabetes.
PMID 18539917·N Engl J Med·2008
4-observational
Are prescribing patterns of antidiabetic medications influenced by fears of litigation?
PMID 18560400·Nat Clin Pract Endocrinol Metab·2008
8-other
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.
PMID 18782641·Lancet·2008
2-rct
Development and validation of the Diabetes Numeracy Test (DNT).
PMID 18452617·BMC Health Serv Res·2008
4-observational
An endangered longhorn beetle associated with old oaks and its possible role as an ecosystem engineer.
PMID 18261146·Conserv Biol·2008
4-observational
Design of the Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) Trial.
PMID 18215589·Am Heart J·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 150 ENTRANCE WAY
SAINT PETERS, MO 63376 - Phone
- (636) 916-9847
Quick Facts
- NPI
- 1669222857
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile